Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

580
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
580

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Storage of Formalin-Fixed Paraffin-Embedded Tissues Negatively Impacts Next-Generation Sequencing: Successful Restoration with a DNA Repair Enzyme.

Clinical chemistry·2026
Same author

Trends in cryoprecipitate transfusion in the United States.

Transfusion·2026
Same author

Clinicopathological characterization of cervical squamous cell carcinoma with <i>PIK3CA</i> hotspot mutation: A single-institution study.

Oncology letters·2026
Same author

The clinical use of cryoprecipitate and fibrinogen concentrate: A scoping review.

Transfusion·2026
Same author

HIV Transmission in a Declining African Epidemic.

medRxiv : the preprint server for health sciences·2026
Same author

Novel RHCE*cE(341A) allele.

Transfusion·2026
Same journal

Investigation of the preanalytical stability of blood donor samples.

Transfusion·2026
Same journal

The need for dried plasma-Still a national issue: Where are we and recommendations.

Transfusion·2026
Same journal

Spray dried plasma manufactured from apheresis and whole blood derived plasma.

Transfusion·2026
Same journal

Identification of a novel ABO*A1.01 allele with c.562C>T (p.Arg188Cys) mutation associated with A<sub>el</sub> phenotype in a Chinese individual.

Transfusion·2026
Same journal

AABB survey on directed blood donation practices.

Transfusion·2026
Same journal

Cost analysis considerations for red blood cell matching to mitigate alloimmunization in patients with sickle cell disease.

Transfusion·2026
See all related articles

Related Experiment Video

Updated: Dec 20, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.1K

How did we rapidly implement a convalescent plasma program?

Alexandra Budhai1, Annie A Wu2, Lucette Hall1

  • 1New York Blood Center Enterprises, New York, New York, USA.

Transfusion
|May 26, 2020
PubMed
Summary
This summary is machine-generated.

This study details the rapid establishment of a COVID-19 convalescent plasma program, distributing over 8000 units and supporting clinical trials. Key challenges remain in optimizing antibody titers, dosage, and transfusion timing for this COVID-19 treatment.

More Related Videos

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.8K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K

Related Experiment Videos

Last Updated: Dec 20, 2025

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.1K
Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
05:57

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases

Published on: August 2, 2022

4.8K
A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood
11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.7K

Area of Science:

  • Immunology
  • Hematology
  • Infectious Diseases

Background:

  • The COVID-19 pandemic spurred investigation into convalescent plasma as a potential therapeutic intervention.
  • Early research explored the efficacy of convalescent plasma for treating SARS-CoV-2 infections.

Purpose of the Study:

  • To describe the establishment and operation of the first U.S. COVID-19 convalescent plasma program.
  • To detail the program's support for emergency use, expanded access, and randomized controlled trials.
  • To outline strategies for scaling plasma collections and distribution.

Main Methods:

  • Implementation of a comprehensive COVID-19 convalescent plasma program.
  • Utilizing single-patient emergency investigational new drug applications and a National Expanded Access Program.
  • Facilitating multiple randomized controlled trials to assess treatment efficacy.
  • Strategic planning, staff redeployment, and collaborative partnerships with healthcare institutions and public health agencies.

Main Results:

  • Rapid distribution of over 8000 convalescent plasma products.
  • Scalability of collections to over 4000 units weekly.
  • Successful fulfillment of hospital demands for COVID-19 treatment.
  • Provided crucial support for ongoing clinical trials evaluating plasma therapy.

Conclusions:

  • The program demonstrated rapid scalability and effectiveness in meeting treatment demands during the pandemic.
  • Collaboration with partners was essential for donor recruitment, testing, and patient access.
  • Further research is needed to optimize convalescent plasma therapy, focusing on antibody titers, dosage, and optimal transfusion timing.